Should Aquestive Therapeutics Be Worried About This FDA Response?
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
These five high-conviction health care stock picks from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest of 2020…
By a count of confirmed COVID-19 cases relative to the total size of the population, Peru is the nation hurt the most by far.
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Credit Suisse has set an Outperform rating and $290 price target on Amgen shares. That target implies more than 20% upside to the stock's recent trading price.
Some small-cap companies will screen as having deep value, but many value stocks are deemed to be "cheap" because they lack any new catalysts and opportunities.
Telemedicine platform provider GoodRx entered the market with a bang on Wednesday.
AC Immune stock was absolutely crushed on Wednesday after the firm announced disappointing results from its midstage Alzheimer’s disease study.
MediciNova has announced progress in its COVID-19 vaccine prototype, which stands out from the rest as it is administered intranasally.
Lack of social distancing and mask-wearing in some parts of the country, coupled with cold weather that will drive people indoors, may cause a spike in deaths in late fall and early winter. A…
It is fair to ask if Illumina's stock has fallen too much on the acquisition announcement. After all, Grail could revolutionize how cancer is screened and ultimately how it is treated.
Illumina shares dipped early Monday after the company announced that it would be making a critical acquisition of Grail.
Truist Securities initiated CorMedix with a Buy rating and a $20 price target. The stock closed below $5 a share on Friday.
Precision oncology company PMV Pharmaceuticals intends to price more than 7.35 million shares for an initial public offering valued up to around $152 million.